The impact of China's National Drug Centralized Procurement Policy on pharmaceutical firm innovation: evidence from a staggered difference-in-differences analysis.

From the first to the third post-treatment years (Post 1 to Post 3), the coefficients exhibit a steady and highly significant upward trend (0.00889, 0.0134, and 0.0170, respectively; all p < 0.01).

also in 132,142 other papers